188 related articles for article (PubMed ID: 30102523)
1. Entry from the Lipid Bilayer: A Possible Pathway for Inhibition of a Peptide G Protein-Coupled Receptor by a Lipophilic Small Molecule.
Bokoch MP; Jo H; Valcourt JR; Srinivasan Y; Pan AC; Capponi S; Grabe M; Dror RO; Shaw DE; DeGrado WF; Coughlin SR
Biochemistry; 2018 Oct; 57(39):5748-5758. PubMed ID: 30102523
[TBL] [Abstract][Full Text] [Related]
2. High-resolution crystal structure of human protease-activated receptor 1.
Zhang C; Srinivasan Y; Arlow DH; Fung JJ; Palmer D; Zheng Y; Green HF; Pandey A; Dror RO; Shaw DE; Weis WI; Coughlin SR; Kobilka BK
Nature; 2012 Dec; 492(7429):387-92. PubMed ID: 23222541
[TBL] [Abstract][Full Text] [Related]
3. Investigating detailed interactions between novel PAR1 antagonist F16357 and the receptor using docking and molecular dynamic simulations.
Readmond C; Wu C
J Mol Graph Model; 2017 Oct; 77():205-217. PubMed ID: 28881236
[TBL] [Abstract][Full Text] [Related]
4. In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist.
Hawes BE; Zhai Y; Hesk D; Wirth M; Wei H; Chintala M; Seiffert D
Eur J Pharmacol; 2015 Sep; 762():221-8. PubMed ID: 26022529
[TBL] [Abstract][Full Text] [Related]
5. Structural Properties of the Human Protease-Activated Receptor 1 Changing by a Strong Antagonist.
Spoerri PM; Kato HE; Pfreundschuh M; Mari SA; Serdiuk T; Thoma J; Sapra KT; Zhang C; Kobilka BK; Müller DJ
Structure; 2018 Jun; 26(6):829-838.e4. PubMed ID: 29731231
[TBL] [Abstract][Full Text] [Related]
6. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
[TBL] [Abstract][Full Text] [Related]
7. Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar.
Aisiku O; Peters CG; De Ceunynck K; Ghosh CC; Dilks JR; Fustolo-Gunnink SF; Huang M; Dockendorff C; Parikh SM; Flaumenhaft R
Blood; 2015 Mar; 125(12):1976-85. PubMed ID: 25587041
[TBL] [Abstract][Full Text] [Related]
8. Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation.
Friebel J; Moritz E; Witkowski M; Jakobs K; Strässler E; Dörner A; Steffens D; Puccini M; Lammel S; Glauben R; Nowak F; Kränkel N; Haghikia A; Moos V; Schutheiss HP; Felix SB; Landmesser U; Rauch BH; Rauch U
Cells; 2021 Dec; 10(12):. PubMed ID: 34944024
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Protease-Activated Receptor (PAR1) Reduces Activation of the Endothelium, Coagulation, Fibrinolysis and Inflammation during Human Endotoxemia.
Schoergenhofer C; Schwameis M; Gelbenegger G; Buchtele N; Thaler B; Mussbacher M; Schabbauer G; Wojta J; Jilma-Stohlawetz P; Jilma B
Thromb Haemost; 2018 Jul; 118(7):1176-1184. PubMed ID: 29864779
[TBL] [Abstract][Full Text] [Related]
10. Conformational Plasticity of Human Protease-Activated Receptor 1 upon Antagonist- and Agonist-Binding.
Spoerri PM; Sapra KT; Zhang C; Mari SA; Kato HE; Kobilka BK; Müller DJ
Structure; 2019 Oct; 27(10):1517-1526.e3. PubMed ID: 31422910
[TBL] [Abstract][Full Text] [Related]
11. Paradigm of Biased PAR1 (Protease-Activated Receptor-1) Activation and Inhibition in Endothelial Cells Dissected by Phosphoproteomics.
van den Eshof BL; Hoogendijk AJ; Simpson PJ; van Alphen FPJ; Zanivan S; Mertens K; Meijer AB; van den Biggelaar M
Arterioscler Thromb Vasc Biol; 2017 Oct; 37(10):1891-1902. PubMed ID: 28818855
[TBL] [Abstract][Full Text] [Related]
12. Does the Lipid Bilayer Orchestrate Access and Binding of Ligands to Transmembrane Orthosteric/Allosteric Sites of G Protein-Coupled Receptors?
Szlenk CT; Gc JB; Natesan S
Mol Pharmacol; 2019 Nov; 96(5):527-541. PubMed ID: 30967440
[TBL] [Abstract][Full Text] [Related]
13. Targeting PAR1: Now What?
Flaumenhaft R; De Ceunynck K
Trends Pharmacol Sci; 2017 Aug; 38(8):701-716. PubMed ID: 28558960
[TBL] [Abstract][Full Text] [Related]
14. Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!
Bhandari B; Mehta B
Recent Adv Cardiovasc Drug Discov; 2014; 9(2):73-7. PubMed ID: 26104312
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel and potent vorapaxar analogues.
Knight E; Robinson E; Smoktunowicz N; Chambers RC; Aliev AE; Inglis GG; Chudasama V; Caddick S
Org Biomol Chem; 2016 Mar; 14(12):3264-74. PubMed ID: 26932831
[TBL] [Abstract][Full Text] [Related]
16. Vorapaxar for the reduction of atherothrombotic events.
Diaz-Ricart M; Escolar G
Drugs Today (Barc); 2014 Nov; 50(11):747-56. PubMed ID: 25525635
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells.
Gandhi DM; Majewski MW; Rosas R; Kentala K; Foster TJ; Greve E; Dockendorff C
Bioorg Med Chem; 2018 May; 26(9):2514-2529. PubMed ID: 29685684
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of potent PAR-1 antagonists based on vorapaxar.
Fan M; Han M; Xia Y; Zhang Y; Chu Y; Bai G; Li W; Li J; Zhao L; He Y; Ma X; Duan Z
Bioorg Med Chem Lett; 2020 Apr; 30(8):127046. PubMed ID: 32122739
[TBL] [Abstract][Full Text] [Related]
19. N-linked glycosylation of protease-activated receptor-1 at extracellular loop 2 regulates G-protein signaling bias.
Soto AG; Smith TH; Chen B; Bhattacharya S; Cordova IC; Kenakin T; Vaidehi N; Trejo J
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):E3600-8. PubMed ID: 26100877
[TBL] [Abstract][Full Text] [Related]
20. Antiapoptotic Effect by PAR-1 Antagonist Protects Mouse Liver Against Ischemia-Reperfusion Injury.
Noguchi D; Kuriyama N; Ito T; Fujii T; Kato H; Mizuno S; Sakurai H; Isaji S
J Surg Res; 2020 Feb; 246():568-583. PubMed ID: 31653415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
